In the 10 year results of HYPO-RT-PC, what was the rate of failure free survival after ultrahypofractionated radiation for prostate cancer?
In a combined analysis of two small trials of osimertinib +/- SRS for up to 10 EGFR mutated NSCLC brain metastases, what was the rate of intracranial PFS at 12 months in each arm?
Answers
72% with 42.7 Gy in 7 fractions vs 65% with conventional fractionation.
68% with SRS v 57% without, which did not reach statistical significance. Notably, the benefit of SRS increased with lesion size. The optimal cutpoint for benefit from SRS was a sum of all lesion diameters of 1.9 cm. | QuadShot News
In a combined analysis of two small trials of osimertinib +/- SRS for up to 10 EGFR mutated NSCLC brain metastases, what was the rate of intracranial PFS at 12 months in each arm?
Answers
72% with 42.7 Gy in 7 fractions vs 65% with conventional fractionation.
68% with SRS v 57% without, which did not reach statistical significance. Notably, the benefit of SRS increased with lesion size. The optimal cutpoint for benefit from SRS was a sum of all lesion diameters of 1.9 cm. | QuadShot News